You are here : Home > Research Entities > Service Hospitalier Frédéric Joliot

Service Hospitalier Frédéric Joliot




Published on 23 March 2015

The Service Hospitalier Frédéric Joliot (SHFJ), directed by Vincent Lebon, is a molecular and functional imaging center located on the Orsay hospital site. It ensures a public service mission and a research and development mission in biomedical imaging and in diagnostic and therapeutic innovation. The aim of this research is to create new imaging tools to improve diagnosis and evaluation of innovative therapeutics in three thematic areas :

  • oncological diseases,
  • neurodegenerative, neuro-inflammatory, psychiatric and addiction disorders,
  • cardiovascular, metabolic and systemic inflammatory diseases.

SHFJ is divided in 3 entities : the Nuclear Medicine Service, that ensures the public service mission of the SHFJ, the In Vivo Molecular Imaging Laboratory (IMIV), a Mixed Research Unit (UMR 1023) belonging to CEA, Inserm and Paris-Sud University and the Laboratory for Methodological Developments in PET (LDM/TEP), based in Caen. The SHFJ has also a branch of the pharmacy for internal use of the Orsay Hospital for 2 activities, namely the preparation of radiopharmaceuticals and the preparations for biomedical research including the experimental medicines one (Arrêté n° 08-065-91 du 23/05/2008).

(click on image to enlarge)


Moreover, the SHFJ is associated with three other Research Entities (Associated Units) : the Medical Magnetic Resonance Imaging and Multi-Modalities Unit (IR4M), the research team in clinical imaging of neurodegenerative diseases, and the Research Team "Child Epilepsy and Cerebral Plasticity".

To carry out their Research, SHFJ researchers have access to platforms, part of the National Infrastructures in Biology and Health France Life Imaging (FLI) et NeurATRIS financed by the Programme of Investments for the Future (PIA) :

  • PRIME (certified IBiSA) : Experimental Molecular Imaging Research Platform, a platform dedicated to preclinical and clinical molecular imaging,
  • IRM 1,5T : a clinical IRM.


Can we trust the calculation of texture indices of CT images? A phantom study
Caramella C., Allorant A., Orlhac F., Bidault F., Asselain B., Ammari S., Jaranowski P., Moussier A., Balleyguier C., Lassau N. and Pitre-Champagnat S.
(18)F-Fludarabine-PET for lymphoma imaging: first-in-man study in DLBCL and CLL patients
Chantepie S., Hovhannisyan N., Guillouet S., Pelage J. P., Ibazizene M., Bodet-Milin C., Carlier T., Gac A. C., Reboursiere E., Vilque J. P., Kraeber-Bodere F., Manrique A., Damaj G., Leporrier M. and Barre L.
Cross-sectional variations of white and grey matter in older hypertensive patients with subjective memory complaints
Chetouani A., Chawki M. B., Hossu G., Kearney-Schwartz A., Chauveau-Beuret F., Bracard S., Roch V., Lebon V., Marie P. Y., Benetos A., Joly L. and Verger A.
Magnetic resonance elastography of the lumbar back muscles: A preliminary study
Creze M., Marc S., Long Yue J., Gagey O., Maitre X. and Marie-France B.
Issues in quantification of registered respiratory gated PET/CT in the lung
Cuplov V., Holman B. F., McClelland J., Modat M., Hutton B. F. and Thielemans K.
Neutrophil hyperactivation correlates with Alzheimer's disease progression
Dong Y., Lagarde J., Xicota L., Corne H., Chantran Y., Chaigneau T., Crestani B., Bottlaender M., Potier M. C., Aucouturier P., Dorothee G., Sarazin M. and Elbim C.
Dopamine Transporter and Reward Anticipation in a Dimensional Perspective: A Multimodal Brain Imaging Study
Dubol M., Trichard C., Leroy C., Sandu A. L., Rahim M., Granger B., Tzavara E. T., Karila L., Martinot J. L. and Artiges E.
Validation of an automatic reference region extraction for the quantification of [(18)F]DPA-714 in dynamic brain PET studies
Garcia-Lorenzo D., Lavisse S., Leroy C., Wimberley C., Bodini B., Remy P., Veronese M., Turkheimer F., Stankoff B. and Bottlaender M.
Intravenous infusion for the controlled exposure to the dual ABCB1 and ABCG2 inhibitor elacridar in nonhuman primates
Goutal S., Langer O., Auvity S., Andrieux K., Coulon C., Caille F., Gervais P., Cisternino S., Decleves X. and Tournier N.
Interval-based reconstruction for uncertainty quantification in PET
Kucharczak F., Loquin K., Buvat I., Strauss O. and Mariano-Goulart D.
Transcutaneous Laryngeal Ultrasonography for Laryngeal Immobility Diagnosis in Patients with Voice Disorders After Thyroid/Parathyroid Surgery
Lazard D. S., Bergeret-Cassagne H., Lefort M., Leenhardt L., Russ G., Frouin F. and Tresallet C.
Texture analysis as a predictor of radiation-induced xerostomia in head and neck patients undergoing IMRT
Nardone V., Tini P., Nioche C., Mazzei M. A., Carfagno T., Battaglia G., Pastina P., Grassi R., Sebaste L. and Pirtoli L.
A post-reconstruction harmonization method for multicenter radiomic studies in PET
Orlhac F., Boughdad S., Philippe C., Stalla-Bourdillon H., Nioche C., Champion L., Soussan M., Frouin F., Frouin V. and Buvat I.
A score combining baseline neutrophilia and primary tumor SUVpeak measured from FDG PET is associated with outcome in locally advanced cervical cancer
Schernberg A., Reuze S., Orlhac F., Buvat I., Dercle L., Sun R., Limkin E., Escande A., Haie-Meder C., Deutsch E., Chargari C. and Robert C.
Imaging PD-L1 Expression with ImmunoPET
Truillet C., Oh H. L. J., Yeo S. P., Lee C. Y., Huynh L. T., Wei J., Parker M. F. L., Blakely C., Sevillano N., Wang Y. H., Shen Y. S., Olivas V., Jami K. M., Moroz A., Jego B., Jaumain E., Fong L., Craik C. S., Chang A. J., Bivona T. G., Wang C. I. and Evans M. J.
Dramatic Increase of Amoxicillin-Induced Crystal Nephropathy Found in a Cohort Study of French Pharmacovigilance Centers
Vodovar D., Thomas L., Mongardon N., Lepeule R., Lebrun-Vignes B., Biour M., Netzer F., Haouache H., Le Beller C. and Dhonneur G.
Impact of Endothelial 18-kDa Translocator Protein on the Quantification of (18)F-DPA-714
Wimberley C., Lavisse S., Brulon V., Peyronneau M. A., Leroy C., Bodini B., Remy P., Stankoff B., Buvat I. and Bottlaender M.
Striatal and Extrastriatal Dopamine Transporter Availability in Schizophrenia and Its Clinical Correlates: A Voxel-Based and High-Resolution PET Study
Artiges E., Leroy C., Dubol M., Prat M., Pepin A., Mabondo A., De Beaurepaire R., Beaufils B., Korwin JP., Galinowski A., d'Albis MA., Santiago-Ribeiro MJ., Granger B., Tzavara ET., Martinot JL. and Trichard C.
Diphenhydramine as a selective probe to study H+-antiporter function at the blood-brain barrier: Application to [C-11]diphenhydramine positron emission tomography imaging
Auvity S., Chapy H., Goutal S., Caille F., Hosten B., Smirnova M., Decleves X., Tournier N. and Cisternino S.
Evaluation of TSPO PET imaging, a marker of glial activation, to study the neuroimmune footprints of morphine exposure and withdrawal
Auvity S., Goutal S., Theze B., Chaves C., Hosten B., Kuhnast B., Saba W., Boisgard R., Buvat I., Cisternino S. and Tournier N.
Susceptibility to morphine-induced glial activation assessed using TSPO PET imaging with F-18-DPA-714 in nonhuman primates
Auvity S., Saba W., Goutal S., Leroy C., Buvat I., Cayia J., Caille F., Bottlaender M., Cisternino S. and Tournier N.
Acute Morphine Exposure Increases the Brain Distribution of [F-18]DPA-714, a PET Biomarker of Glial Activation in Nonhuman Primates
Auvity S., Saba W., Goutal S., Leroy C., Buvat I., Cayla J., Caille F., Bottlaender M., Cisternino S. and Tournier N.
Shear Wave Elastography in Thyroid Nodules with Indeterminate Cytology: Results of a Prospective Bicentric Study
Bardet S., Ciappuccini R., Pellot-Barakat C., Monpeyssen H., Michels JJ., Tissier F., Blanchard D., Menegaux F., de Raucourt D., Lefort M., Reznik Y., Rouxel A., Heutte N., Brenac F., Leconte A., Buffet C., Clarisse B. and Leenhardt L.
Assessment of P-Glycoprotein Transport Activity at the Human Blood Retina Barrier with (R)-C-11-Verapamil PET
Bauer M., Karch R., Tournier N., Cisternino S., Wadsak W., Hacker M., Marhofer P., Zeitlinger M. and Langer O.
[18F]-FMISO PET study of hypoxia in gliomas before surgery: correlation with molecular markers of hypoxia and angiogenesis
Bekaert L., Valable S., Lechapt-Zalcman E., Ponte K., Collet S., Constans JM., Levallet G., Bordji K., Petit E., Branger P., Emery E., Manrique A., Barre L., Bernaudin M. and Guillamo JS.
Sonographic Dynamic Description of the Laryngeal Tract: Definition of Quantitative Measures to Characterize Vocal Fold Motion and Estimation of Their Normal Values
Bergeret-Cassagne H., Lazard DS., Lefort M., Hachi S., Leenhardt L., Menegaux F., Russ G., Tresallet C. and Frouin F.
Individual remyelination profiles in cortical grey matter and in white matter lesions in multiple sclerosis: a combined PET and MTR study
Bodini B., Poirion E., Battaglini M., Veronese M., Lubetzki C., Bottlaender M., De Stefano N., Turkheimer F. and Stankoff B.
Heterogeneity in individual patterns of microglial activation in multiple sclerosis measured non-invasively with 18F-DPA-714 PET
Bodini B., Poirion E., Garcia-Lorenzo D., Battaglini M., Luapre C., Bera G., Maillart E., Papeix C., Bottlaender M. and Stankoff B.
Physiological variations of SUV and textural indices in normal breast tissue as a function of age and body mass index in FDG-PET.
Boughdad S., Nioche C., Orlhac F., Champion L. and Buvat I.
Variations in SUV and textural indices in breast tissue satellite to breast cancer compared to normal breast tissue in FDG-PET.
Boughdad S., Nioche C., Orlhag F., Champion L. and Buvat I.
1 - 30Next